About this trial
This study aims to evaluate the efficacy and safety of adebrelimab combined with the AG regimen in patients with unresectable locally advanced or metastatic pancreatic cancer who have received at least one prior line of systemic therapy but have not undergone gemcitabine-based treatment.
Eligibility criteria
Qualifiers
Sign informed consent;
Aged 18-75 years (inclusive);
Histologically or cytologically confirmed pancreatic cancer;
Unresectable locally advanced or metastatic pancreatic cancer, as determined by the investigator;
Disqualifiers
The subject has any known active autoimmune disease;
Subjects have any complications requiring systemic treatment with corticosteroids such as prednisone (> 10mg/ day) or have used immunosuppressive drugs within 14 days prior to initial administration;
Subjects received tumor vaccines or other immune-activating antitumor drugs (such as interferon, interleukin, thymosin, or immune cell therapy) within 1 month prior to initial administration;
Subjects are participating in another clinical trial or have received a drug intervention from another clinical trial within 4 weeks prior to the first dose;
Trial design
Treatments tested in this trial
- Adebrelimab
- AG
Treatment groups
Sponsors and collaborators
Jin Xu
Lead sponsor
Fudan University
Sponsor institution